TAGRISSO® (osimertinib) plus chemotherapy demonstrated

Results support potential for a new treatment option that builds on the benefit of first-line standard of care TAGRISSO monotherapy

... | May 17, 2023

Related Keywords

China , Poland , Cambridge , Cambridgeshire , United Kingdom , Japan , United States , America , Polish , American , Susan Galbraith , Daiichi Sankyo , Archives Pathology Lab , Astrazeneca , Dana Farber Cancer Institute , World Health Organization , Single Institution Study , Lung Ambition Alliance , Lungevity Foundation , International Agency For Research On Cancer , Executive Vice President , Prescription Information , Patient Information , South America , Rare Diseases , International Agency , Lung Fact , Accessed May , Histological Samples , Non Small Cell Lung Cancer , Systematic Review , Intj Clin Exp , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing , Kinase Inhibitor , Lung Cancer , Available Methods , Their Use , Tumor Tissue , Cancer Biomarkers , Present Status , Mediated Resistance , Astrazeneca Plc Stock Exchange , News , Information , Press Release , Results , Support , Potential , Or , Few , Treatment , Option , Hat , Builds , N , The , Benefit , F , Standard , Mare , Agrisso Azn Gb0009895292 ,